spacer
home > epc > spring 2009 > contingency planning
PUBLICATIONS
European Pharmaceutical Contractor

Contingency Planning

In recent years, many popular prescription drugs, over-thecounter products and medical devices have been forced off the market due to safety concerns. When a regulatory agency decides that a medication presents substantial adverse reactions in the general population, the resulting panic among consumers and the recall process itself can become a challenge to effectively manage. Some companies tend to adopt an ‘it won’t happen to us’ mentality when it comes to product recalls, but the reality is that product recalls can happen to any biopharmaceutical and device company and every second counts in the recall process.

The best strategy is a proactive one. Even if a company thinks it can handle the call volume and other tasks associated with a recall, having a contingency plan in place by researching a capable, experienced outsourcing provider who can step in and provide support is strongly recommended.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Sameer Thapar is Director of Global Safety Surveillance and Pharmacovigilance for Omnicare Clinical Research. He is a Doctor of Pharmacy (PharmD) and is licensed pharmacist with over 12 years of pharmaceutical industry experience. His expertise in the pharmacovigilance arena spans the realm of regulatory adherence of Ethics Committees’ and Regulatory Authorities’ guidelines, leading domestic and international Health Authority inspections, to processing, interpreting and submitting clinical (Phase I-IV) safety reports and post-marketing adverse events.

spacer
Sameer Thapar
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement